Vertex begins Phase II development programme for VX-950 (Chronic Hepatitis C)

Vertex begins Phase II development programme for VX-950
InPharm.com - Drug News from Espicom] Reports on Hepatitis C from Piribo Vertex Pharmaceuticals has initiated a VX-950, an investigational oral hepatitis C (HCV) protease inhibitor for the

Non-invasive markers of liver damage effective in HIV / hepatitis C co-infected patients
Aidsmap - Markers of liver damage due to hepatitis C infection that can be measured from blood samples are could be used in HIV / hepatitis C co-infected patients in place

Texas scientists discover how a hepatitis C protein promotes liver cancer
innovations report - Branch at Galveston (UTMB) have identified a key biochemical connection between the hepatitis C virus and liver cancer is that one of the hepatitis C virus proteins targets a cell